Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Arrowhead Pharmaceuticals In (ARWR)

435 + Investors. Track Smart Money conviction in ARWR. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +34
Streak
4Q ▲
Buyers last Q
58%

Smart Money Signals — ARWR

Based on 437 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 4 quarters in a row

last 6Q
For 4 consecutive quarters, more hedge funds added ARWR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
437 hedge funds hold ARWR right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +69% more funds vs a year ago

fund count last 6Q
+179 new funds entered over the past year (+69% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 58% buying

271 buying196 selling
Last quarter: 271 funds bought or added vs 196 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-28 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 59 → 64 → 133 → 105. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

49% of holders stayed for 2+ years

■ 49% conviction (2yr+) ■ 20% medium ■ 31% new
215 out of 437 hedge funds have held ARWR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares +3%, value -39%

Value
-38%
Shares
+2%
Last quarter: funds added +3% more shares while total portfolio value only changed -39%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
🚀

Acceleration phase — new buyers rushing in

40 → 59 → 64 → 133 → 105 new funds/Q
New funds entering each quarter: 59 → 64 → 133 → 105. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Deep conviction — 62% of holders stayed 2+ years

■ 62% veterans ■ 7% 1-2yr ■ 31% new
Of 454 current holders: 283 (62%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
✅

Strong quality — 38% AUM from major funds

38% from top-100 AUM funds
60 of 437 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.8
out of 10
Moderate Exit Risk
Exit risk score 4.8/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — ARWR

In 2026 Q1, 271 hedge funds were net buyers of ARWR (105 opened a new position, 166 added to an existing one), while 196 reduced or exited (125 trimmed, 71 sold completely) — a 58% buyer ratio, indicating a slight buying edge. This marks 4 consecutive quarters of net institutional buying — a persistent conviction signal. 38% of total institutional value in ARWR is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +34 funds (more new holders than closures). Total institutional holders: 437.

Hedge Fund Ownership: ARWR

How many hedge funds hold ARWR — quarterly history vs. share price
Quarterly hedge fund ownership of ARWR vs. share price

Market Analysis: ARWR

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ARWR

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Arrowhead Pharmaceuticals In (ARWR) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much ARWR has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 78d ago
ARWR
+29.3%
XLV
+2.8%

ARWR outperformed XLV by +26.5% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 33d ago
ARWR
+5.7%
XLV
+3.9%

Since the filing became public, ARWR outperformed XLV by +1.8% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

29 top-rated funds 6 high-conviction
Consensus
6.4
/ 10
breadth
×
Elite
3.6
/ 10
conviction
Hedge Fund Positioning: ARWR
435 + Investors

Track Smart Money conviction in ARWR. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 435 403 7.94%
13F Shares 123M 119M 2.6%
Total Value $7.55B $12.36B -38.93%
New Positions 104 133 -29
Increased Positions 162 129 +33
Closed Positions 72 30 +42
Reduced Positions 118 103 +15
Total Calls 13 14 -7.14%
Total Puts 11 8 37.5%
PUT/CALL Ratio 0.85 0.57 Neutral

Statistics: ARWR

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

435 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ARWR. Verified SEC 13F-HR filings.

QUARTER:
Top 25 ARWR holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Western Financial Corp/CA 20.13% 820,239 $51.4M
2 Avoro Capital Advisors LLC 6.60% 10,699,999 $670.9M
3 Privium Fund Management B.V. 4.79% 366,936 $23.0M
4 M28 Capital Management LP 4.29% 36,851 $2.3M
5 Act Capital Management, LLC 4.07% 82,500 $5.2M
6 Vestal Point Capital, LP 3.99% 2,275,000 $142.6M
7 Ishara Investments LP 3.29% 55,350 $3.5M
8 Wealth Effects LLC 3.18% 143,300 $9.0M
9 Siren, L.L.C. 2.81% 1,615,476 $101.3M
10 Tetragon Partners GP Ltd 1.55% 127,198 $8.0M
11 Exome Asset Management LLC 1.48% 45,721 $2.9M
12 Orion Investment Co 1.24% 62,535 $3.9M
13 Deerfield Management Company, L.P. 1.16% 1,573,297 $98.6M
14 Rhenman & Partners Asset Management AB 1.12% 144,500 $9.1M
15 Pinion Investment Advisors, LLC 1.10% 75,000 $4.7M
16 Platinum Investment Management Ltd 1.02% 64,752 $4.1M
17 Capstone Capital Management Ltd 0.99% 15,740 $987K
18 Fred Alger Management, LLC 0.92% 3,342,493 $209.6M
19 Summit Partners Public Asset Management, LLC 0.91% 540,144 $33.9M
20 Integral Health Asset Management, LLC 0.90% 300,000 $18.8M
21 Baker BROS. Advisors LP 0.72% 1,992,783 $124.9M
22 Hood River Capital Management LLC 0.66% 1,056,534 $66.2M
23 Affinity Asset Advisors, LLC 0.65% 200,000 $12.5M
24 Ares Systematic Credit Ltd 0.60% 13,169 $759K
25 Driehaus Capital Management LLC 0.55% 1,190,335 $74.6M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Arrowhead Pharmaceuticals In (ARWR)

What does the Smart Money Trend signal show for ARWR?

Buying streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds added ARWR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ARWR?

Slight buying edge — 58% buying: Last quarter: 271 funds bought or added vs 196 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for ARWR holders?

Strong quality — 38% AUM from major funds: 60 of 437 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held ARWR?

49% of holders stayed for 2+ years: 215 out of 437 hedge funds have held ARWR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Arrowhead Pharmaceuticals In (ARWR) following the 2026 Q1 hedge fund 13F filings?

As of today, ARWR has moved +5.7% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of +1.8%. Since the quarter end (March 31, 2026), ARWR has gained +29.3% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →